1
|
Wang S, Zhang YX, Huang T, Sui JN, Lu J, Chen XJ, Wang KK, Xi XD, Li JM, Huang JY, Chen B. Mutation profile and associated clinical features in Chinese patients with cytogenetically normal acute myeloid leukemia. Int J Lab Hematol 2018; 40:408-418. [PMID: 29573577 DOI: 10.1111/ijlh.12802] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2017] [Accepted: 01/29/2018] [Indexed: 01/24/2023]
Affiliation(s)
- S. Wang
- State Key Laboratory of Medical Genomics; Shanghai Institute of Hematology; Rui Jin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine; Shanghai China
| | - Y.-X. Zhang
- State Key Laboratory of Medical Genomics; Shanghai Institute of Hematology; Rui Jin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine; Shanghai China
| | - T. Huang
- State Key Laboratory of Medical Genomics; Shanghai Institute of Hematology; Rui Jin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine; Shanghai China
| | - J.-N. Sui
- State Key Laboratory of Medical Genomics; Shanghai Institute of Hematology; Rui Jin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine; Shanghai China
| | - J. Lu
- State Key Laboratory of Medical Genomics; Shanghai Institute of Hematology; Rui Jin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine; Shanghai China
| | - X.-J. Chen
- State Key Laboratory of Medical Genomics; Shanghai Institute of Hematology; Rui Jin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine; Shanghai China
| | - K.-K. Wang
- State Key Laboratory of Medical Genomics; Shanghai Institute of Hematology; Rui Jin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine; Shanghai China
| | - X.-D. Xi
- State Key Laboratory of Medical Genomics; Shanghai Institute of Hematology; Rui Jin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine; Shanghai China
| | - J.-M. Li
- State Key Laboratory of Medical Genomics; Shanghai Institute of Hematology; Rui Jin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine; Shanghai China
| | - J.-Y. Huang
- State Key Laboratory of Medical Genomics; Shanghai Institute of Hematology; Rui Jin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine; Shanghai China
| | - B. Chen
- State Key Laboratory of Medical Genomics; Shanghai Institute of Hematology; Rui Jin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine; Shanghai China
| |
Collapse
|
2
|
Molecular methods. Clin Immunol 2013. [DOI: 10.1016/b978-0-7234-3691-1.00112-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
3
|
Bajpayee M, Pandey AK, Parmar D, Dhawan A. Current Status of Short-Term Tests for Evaluation of Genotoxicity, Mutagenicity, and Carcinogenicity of Environmental Chemicals and NCEs. Toxicol Mech Methods 2012; 15:155-80. [PMID: 20021080 DOI: 10.1080/15376520590945667] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
The advent of the industrial revolution has seen a significant increase in the number of new chemical entities (NCEs) released in the environment. It becomes imperative to check the toxic potential of NCEs to nontarget species before they are released for commercial purposes because some of these may exert genotoxicity, mutagenicity, or carcinogenicity. Exposure to such compounds produces chemical changes in DNA, which are generally repaired by the DNA repair enzymes. However, DNA damage and its fixation may occur in the form of gene mutations, chromosomal damage, and numerical chromosomal changes and recombination. This may affect the incidence of heritable mutations in man and may be transferred to the progeny or lead to the development of cancer. Hence, adequate tests on NCEs have to be undertaken for the risk assessment and hazard prediction. Compounds that are positive in tests that detect such damages have the potential to be human mutagens/carcinogens. Only long-term animal bioassays, involving lifetime studies on animals, were used earlier to classify substances as mutagens/carcinogens. These tests were cumbersome and time consuming and required a lot of facilities and personnel. Short-term tests, therefore, were brought into practice. A "battery" of three to four of these short-term tests has been proposed now by a number of regulatory authorities for the classification of compounds as mutagenic or carcinogenic. This review deals with the current status of these short-term tests.
Collapse
Affiliation(s)
- Mahima Bajpayee
- Developmental Toxicology Division, Industrial Toxicology Research Center, M.G. Marg, LucknowIndia
| | | | | | | |
Collapse
|
4
|
Foster N, Paulsson K, Sales M, Cunningham J, Groves M, O'Connor N, Begum S, Stubbs T, McMullan DJ, Griffiths M, Pratt N, Tauro S. Molecular characterisation of a recurrent, semi-cryptic RUNX1 translocation t(7;21) in myelodysplastic syndrome and acute myeloid leukaemia. Br J Haematol 2010; 148:938-43. [PMID: 20064152 DOI: 10.1111/j.1365-2141.2009.08039.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
A proportion of cytogenetic abnormalities in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) may escape detection by high-resolution genomic technologies, but can be identified by conventional cytogenetic and molecular analysis. Here, we report the detection of a reciprocal translocation t(7;21)(p22;q22) in the marrow of two adults with MDS and AML, using conventional cytogenetic analysis and fluorescence-in situ-hybridization (FISH). Reverse-transcription polymerase chain reaction (RT-PCR) and sequence analysis identified a fusion between RUNX1 and the gene encoding ubiquitin specific peptidase-42 (USP42), with splice-variants and variable break-points within RUNX1. Combined cytomorphology and FISH studies in MDS marrow revealed abnormal RUNX1 signals within megakaryocytes, suggesting that the acquisition of t(7;21)(p22;q22) does not confer complete differentiation arrest and may represent an early genetic event in leukaemogenesis. Single nucleotide polymorphism-arrays failed to detect additional sub-microscopic genomic changes predisposing to or associated with t(7;21). Molecular analysis of 100 MDS and AML marrow specimens by RT-PCR did not reveal new cases with the RUNX1-USP42 fusion. Thus, our studies have identified t(7;21)(p22;q22) as a rare but recurrent abnormality in MDS/AML, with the existence of alternative spliced forms of the RUNX1-USP42 transcript in different patients. Further studies are required to identify the potential contribution of these splice-variants to disease heterogeneity.
Collapse
Affiliation(s)
- Nicola Foster
- Department of Cytogenetics, Ninewells Hospital and Medical School, Dundee, UK
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Abstract
Aptamers are DNA or RNA oligonucleotide sequences that selectively bind to their target with high affinity and specificity. They are obtained using an iterative selection protocol called SELEX. Several small molecules and proteins have been used as targets. Recently, a variant of this methodology, known as cell-SELEX, has been developed for a new generation of aptamers, which are capable of recognizing whole living cells. We have used this methodology for the selection of aptamers, which show high affinity and specificity for several cancer cells. In this chapter, we describe (1) the process followed for the generation of aptamers capable of recognizing acute leukemia cells (CCRF-CEM cells) and (2) the method of enhancing the selectivity and sensitivity of these aptamers by conjugation with a dual-nanoparticle system, which combines magnetic nanoparticles (MNP) and fluorescent silica nanoparticles (FNP). Specifically, the selected aptamers, which showed dissociation constants in the nanomolar range, have been coupled to MNPs in order to selectively collect and enrich cells from complex matrices, including blood samples. The additional coupling of the aptamer to FNPs offers an excellent and highly sensitive method for detecting cancer cells. In order to prove the potential of this rapid and low-cost method for diagnostic purposes, confocal microscopy was used to confirm the specific collection and detection of target cells in concentrations as low as 250 cells. The final fluorescence of the cells labeled with the nanoparticles was quantified using a fluorescence microplate reader.
Collapse
|
6
|
Abstract
Patients with acute myeloid leukemia (AML) harboring three or more acquired chromosome aberrations in the absence of the prognostically favorable t(8;21)(q22;q22), inv(16)(p13q22)/t(6;16)(p13;q22), and t(15;17)(q22;q21) aberrations form a separate category - AML with a complex karyotype. They constitute 10% to 12% of all AML patents, with the incidence of complex karyotypes increasing with the more advanced age. Recent studies using molecular-cytogenetic techniques (spectral karyotyping [SKY], multiplex fluorescence in situ hybridization [M-FISH]) and array comparative genomic hybridization (a-CGH) considerably improved characterization of previously unidentified, partially identified, or cryptic chromosome aberrations, and allowed precise delineation of genomic imbalances. The emerging nonrandom pattern of abnormalities includes relative paucity, but not absence, of balanced rearrangements (translocations, insertions, or inversions), predominance of aberrations leading to loss of chromosome material (monosomies, deletions, and unbalanced translocations) that involve, in decreasing order, chromosome arms 5q, 17p, 7q, 18q, 16q, 17q, 12p, 20q, 18p, and 3p, and the presence of recurrent, albeit less frequent and often hidden (in marker chromosomes and unbalanced translocations) aberrations leading to overrepresentation of segments from 8q, 11q, 21q, 22q, 1p, 9p, and 13q. Several candidate genes have been identified as targets of genomic losses, for example, TP53, CTNNA1, NF1, ETV6, and TCF4, and amplifications, for example, ERG, ETS2, APP, ETS1, FLI1, MLL, DDX6, GAB2, MYC, TRIB1, and CDX2. Treatment outcomes of complex karyotype patients receiving chemotherapy are very poor. They can be improved to some extent by allogeneic stem cell transplantation in younger patients. It is hoped that better understanding of genomic alterations will result in identification of novel therapeutic targets and improved prognosis in patients with complex karyotypes.
Collapse
|
7
|
Abstract
The method of spectral karyotyping (SKY) is based on a combination of the technologies of charge-coupled device imaging and spectrometry. The engineering feasibility has been realized in the SpectraCube system from Applied Spectral Imaging Inc., and it allows the simultaneous identification of all 24 human chromosomes. This is performed by characterizing the spectral signature of every image pixel in relation to a fluorochrome combinatorial library translating the image and spectral information into chromosome classification. Applications for SKY include pre- and postnatal characterization of certain numerical and structural rearrangements and complex karyotypes and highly informative analysis of sample materials with only single or few cells available for investigation.
Collapse
|
8
|
Belmont JW. Molecular methods. Clin Immunol 2008. [DOI: 10.1016/b978-0-323-04404-2.10101-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
9
|
Davidsson J, Paulsson K, Johansson B. Multicolor fluorescence in situ hybridization characterization of cytogenetically polyclonal hematologic malignancies. ACTA ACUST UNITED AC 2006; 163:180-3. [PMID: 16337865 DOI: 10.1016/j.cancergencyto.2005.05.013] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2005] [Revised: 05/30/2005] [Accepted: 05/31/2005] [Indexed: 11/28/2022]
Abstract
Several different investigations and methodologies have provided data supporting a monoclonal origin of neoplasia. For example, the vast majority of neoplastic disorders are cytogenetically monoclonal. Occasionally, however, clones with unrelated karyotypic anomalies are found, as, for example, in approximately 2% of acute myeloid leukemias (AML), myelodysplastic syndromes (MDS), and chronic myeloproliferative disorders (CMD). Whether such a cytogenetic polyclonality represents a polyclonal origin or whether different clones share a submicroscopic primary change, indicating a monoclonal origin, remains to be elucidated. Our objective was to ascertain if cryptic aberrations can be found in cytogenetically polyclonal hematologic malignancies using multicolor fluorescence in situ hybridization (M-FISH). Fourteen AML, MDS, and CMD cases were investigated. In none of these was a cryptic aberration found, common to all subclones, although the karyotypes were revised in two AMLs and one MDS. Thus, all malignancies were still classified as polyclonal after the M-FISH analyses. Based on the present results, we conclude that M-FISH, in general, does not reveal primary cryptic aberrations supporting a monoclonal origin of cytogenetically polyclonal hematologic malignancies.
Collapse
Affiliation(s)
- Josef Davidsson
- Department of Clinical Genetics, Lund University Hospital, SE - 221 85 Lund, Sweden.
| | | | | |
Collapse
|
10
|
Cocco L, Martelli AM, Fiume R, Faenza I, Billi AM, Manzoli FA. Signal transduction within the nucleus: Revisiting phosphoinositide inositide–specific phospholipase Cβ1. ACTA ACUST UNITED AC 2006; 46:2-11. [PMID: 16846636 DOI: 10.1016/j.advenzreg.2006.01.012] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Lucio Cocco
- Cellular Signaling Laboratory, Department of Anatomical Sciences, University of Bologna, via Irnerio 48, 40126 Bologna, Italy.
| | | | | | | | | | | |
Collapse
|
11
|
Martelli AM, Follo MY, Evangelisti C, Falà F, Fiume R, Billi AM, Cocco L. Nuclear inositol lipid metabolism: more than just second messenger generation? J Cell Biochem 2005; 96:285-92. [PMID: 16088939 DOI: 10.1002/jcb.20527] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
A distinct polyphosphoinositide cycle is present in the nucleus, and growing evidence suggests its importance in DNA replication, gene transcription, and apoptosis. Even though it was initially thought that nuclear inositol lipids would function as a source for second messengers, recent findings strongly indicate that lipids present in the nucleus also fulfil other roles. The scope of this review is to highlight the most intriguing advances made in the field over the last few years, such as the possibility that nuclear phosphatidylinositol (4,5) bisphosphate is involved in maintaining chromatin in a transcriptionally active conformation, the new emerging roles for intranuclear phosphatidylinositol (3,4,5) trisphosphate and phosphoinositide 3-kinase, and the evidence which suggests a tight relationship between a decreased level of nuclear phosphoinositide specific phospholipase C-beta1 and the evolution of myelodisplastic syndrome into acute myeloid leukemia.
Collapse
Affiliation(s)
- Alberto M Martelli
- Dipartimento di Scienze Anatomiche Umane e Fisiopatologia dell'Apparato Locomotore, Sezione di Anatomia Umana, Cell Signalling Laboratory, Università di Bologna, 40126 Bologna, Italy
| | | | | | | | | | | | | |
Collapse
|
12
|
Alvarez S, Cigudosa JC. Gains, losses and complex karyotypes in myeloid disorders: a light at the end of the tunnel. Hematol Oncol 2005; 23:18-25. [PMID: 16142824 DOI: 10.1002/hon.744] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Complex karyotypes are seen in approximately 15% of de novo MDS/AML and in up to 50% of therapy-related MDS/AML. These patients represent a therapeutic challenge for which no current treatment approach is satisfactory. Therefore, a large number of genetic studies using cytogenetic molecular techniques have been performed to better define the chromosomal abnormalities in this poor-prognosis group. On the basis of the available data from several studies of AML with complex karyotypes, similar findings on recurrent breakpoints and frequently lost and gained chromosomal regions have been observed. The most frequent rearrangements, in all the published series, were unbalanced translocations leading to loss of chromosomal material. Overall, loss of 5q and/or 7q chromosomal material seemed the more common event, and losses of 5q, 7q, and 17p in combination were observed in many cases. Overrepresented chromosomal material from 8q, 11q23, 21q and 22q was found recurrently and in several cases this was due to the amplification of the MLL (located at 11q23) and AML1/RUNX1 (located at 22q22) genes. As a result of these findings, the presence of MLL copy gain/amplifications or losses of the short arm of chromosome 17, in association with 5/5q, have been found to be indicators of an extremely poor prognosis. Interestingly, this non-random pattern of DNA gains and losses, that characterizes AML cases with complex karyotypes, affects the gene expression pattern, and a specific expression profile, characterized by the upregulation of genes involved in the DNA repair and chromosome segregation pathways, has been recently reported. Therefore, a comprehensive genome-wide analysis of patients with AML or MDS with complex karyotypes has led to a better characterization of chromosomal aberrations. These specific alterations could be used in the near future as therapeutic targets or markers for the risk stratification of patients, detection of minimal residual disease and the development of new therapeutic interventions.
Collapse
MESH Headings
- Chromosome Segregation/genetics
- Chromosomes, Human/genetics
- Chromosomes, Human/metabolism
- Core Binding Factor Alpha 2 Subunit/genetics
- Core Binding Factor Alpha 2 Subunit/metabolism
- DNA Repair/genetics
- Gene Amplification/genetics
- Gene Expression Profiling/methods
- Gene Expression Regulation, Leukemic/genetics
- Genome, Human/genetics
- Histone-Lysine N-Methyltransferase
- Humans
- Karyotyping
- Leukemia, Myeloid, Acute/genetics
- Leukemia, Myeloid, Acute/metabolism
- Leukemia, Myeloid, Acute/therapy
- Myelodysplastic Syndromes/genetics
- Myelodysplastic Syndromes/metabolism
- Myelodysplastic Syndromes/therapy
- Myeloid-Lymphoid Leukemia Protein/genetics
- Myeloid-Lymphoid Leukemia Protein/metabolism
- Neoplasm Proteins/genetics
- Neoplasm Proteins/metabolism
- Neoplasm, Residual/genetics
- Neoplasm, Residual/metabolism
- Neoplasm, Residual/therapy
- Risk Factors
- Translocation, Genetic
Collapse
Affiliation(s)
- Sara Alvarez
- Cytogenetics Unit, Centro Nacional de de Investigaciones Oncológicas (CNIO), Madrid, Spain
| | | |
Collapse
|
13
|
Ballen KK, Hasserjian RP. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 2-2005. A 39-year-old woman with headache, stiff neck, and photophobia. N Engl J Med 2005; 352:274-83. [PMID: 15659728 DOI: 10.1056/nejmcpc049034] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- Karen K Ballen
- Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, USA
| | | |
Collapse
|